vs
ICU MEDICAL INC（ICUI）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是ICU MEDICAL INC的1.7倍（$906.4M vs $540.7M），Rollins, Inc.净利率更高（11.9% vs -2.9%，领先14.8%），Rollins, Inc.同比增速更快（10.2% vs -14.1%），Rollins, Inc.自由现金流更多（$111.2M vs $36.0M），过去两年Rollins, Inc.的营收复合增速更高（0.8% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
ICUI vs ROL — 直观对比
营收规模更大
ROL
是对方的1.7倍
$540.7M
营收增速更快
ROL
高出24.4%
-14.1%
净利率更高
ROL
高出14.8%
-2.9%
自由现金流更多
ROL
多$75.3M
$36.0M
两年增速更快
ROL
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $906.4M |
| 净利润 | $-15.7M | $107.8M |
| 毛利率 | 37.5% | — |
| 营业利润率 | 1.0% | 16.1% |
| 净利率 | -2.9% | 11.9% |
| 营收同比 | -14.1% | 10.2% |
| 净利润同比 | 34.0% | 2.5% |
| 每股收益（稀释后） | $-0.63 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $540.7M | $912.9M | ||
| Q3 25 | $537.0M | $1.0B | ||
| Q2 25 | $548.9M | $999.5M | ||
| Q1 25 | $604.7M | $822.5M | ||
| Q4 24 | $629.8M | $832.2M | ||
| Q3 24 | $589.1M | $916.3M | ||
| Q2 24 | $596.5M | $891.9M |
净利润ICUIROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $-15.7M | $116.4M | ||
| Q3 25 | $-3.4M | $163.5M | ||
| Q2 25 | $35.3M | $141.5M | ||
| Q1 25 | $-15.5M | $105.2M | ||
| Q4 24 | $-23.8M | $105.7M | ||
| Q3 24 | $-33.0M | $136.9M | ||
| Q2 24 | $-21.4M | $129.4M |
毛利率ICUIROL
| Q1 26 | — | — | ||
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — |
营业利润率ICUIROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | 1.0% | 17.5% | ||
| Q3 25 | 2.6% | 21.9% | ||
| Q2 25 | 1.9% | 19.8% | ||
| Q1 25 | 2.1% | 17.3% | ||
| Q4 24 | 6.0% | 18.1% | ||
| Q3 24 | 1.4% | 20.9% | ||
| Q2 24 | 1.3% | 20.4% |
净利率ICUIROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | -2.9% | 12.8% | ||
| Q3 25 | -0.6% | 15.9% | ||
| Q2 25 | 6.4% | 14.2% | ||
| Q1 25 | -2.6% | 12.8% | ||
| Q4 24 | -3.8% | 12.7% | ||
| Q3 24 | -5.6% | 14.9% | ||
| Q2 24 | -3.6% | 14.5% |
每股收益（稀释后）ICUIROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $-0.63 | $0.24 | ||
| Q3 25 | $-0.14 | $0.34 | ||
| Q2 25 | $1.43 | $0.29 | ||
| Q1 25 | $-0.63 | $0.22 | ||
| Q4 24 | $-0.97 | $0.22 | ||
| Q3 24 | $-1.35 | $0.28 | ||
| Q2 24 | $-0.88 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | $2.1B | $1.4B |
| 总资产 | $4.1B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资ICUIROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | — | $100.0M | ||
| Q3 25 | — | $127.4M | ||
| Q2 25 | — | $123.0M | ||
| Q1 25 | — | $201.2M | ||
| Q4 24 | $308.6M | $89.6M | ||
| Q3 24 | $312.5M | $95.3M | ||
| Q2 24 | $302.6M | $106.7M |
总债务ICUIROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ICUIROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.1B | $1.4B | ||
| Q3 25 | $2.1B | $1.5B | ||
| Q2 25 | $2.1B | $1.4B | ||
| Q1 25 | $2.0B | $1.4B | ||
| Q4 24 | $2.0B | $1.3B | ||
| Q3 24 | $2.0B | $1.3B | ||
| Q2 24 | $2.0B | $1.2B |
总资产ICUIROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $4.1B | $3.1B | ||
| Q3 25 | $4.1B | $3.2B | ||
| Q2 25 | $4.1B | $3.2B | ||
| Q1 25 | $4.2B | $2.9B | ||
| Q4 24 | $4.2B | $2.8B | ||
| Q3 24 | $4.3B | $2.8B | ||
| Q2 24 | $4.3B | $2.8B |
负债/权益比ICUIROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $111.2M |
| 自由现金流率自由现金流/营收 | 6.6% | 12.3% |
| 资本支出强度资本支出/营收 | 4.6% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $621.1M |
8季度趋势，按日历期对齐
经营现金流ICUIROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $60.6M | $164.7M | ||
| Q3 25 | $56.7M | $191.3M | ||
| Q2 25 | $11.2M | $175.1M | ||
| Q1 25 | $51.3M | $146.9M | ||
| Q4 24 | $40.2M | $188.2M | ||
| Q3 24 | $36.1M | $146.9M | ||
| Q2 24 | $82.0M | $145.1M |
自由现金流ICUIROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $36.0M | $159.0M | ||
| Q3 25 | $27.6M | $182.8M | ||
| Q2 25 | $-8.5M | $168.0M | ||
| Q1 25 | $36.7M | $140.1M | ||
| Q4 24 | $16.1M | $184.0M | ||
| Q3 24 | $16.2M | $139.4M | ||
| Q2 24 | $62.5M | $136.4M |
自由现金流率ICUIROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 6.6% | 17.4% | ||
| Q3 25 | 5.1% | 17.8% | ||
| Q2 25 | -1.5% | 16.8% | ||
| Q1 25 | 6.1% | 17.0% | ||
| Q4 24 | 2.6% | 22.1% | ||
| Q3 24 | 2.7% | 15.2% | ||
| Q2 24 | 10.5% | 15.3% |
资本支出强度ICUIROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 4.6% | 0.6% | ||
| Q3 25 | 5.4% | 0.8% | ||
| Q2 25 | 3.6% | 0.7% | ||
| Q1 25 | 2.4% | 0.8% | ||
| Q4 24 | 3.8% | 0.5% | ||
| Q3 24 | 3.4% | 0.8% | ||
| Q2 24 | 3.3% | 1.0% |
现金转化率ICUIROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | 0.32× | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
ROL
暂无分部数据
